Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion.
10.3341/kjo.2009.23.4.259
- Author:
Jin Young KIM
1
;
Sung Pyo PARK
Author Information
1. Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. sungpyo@hanafos.com
- Publication Type:Original Article ; Comparative Study
- Keywords:
Bevacizumab;
Branch retinal vein occlusion;
Macular edema;
Triamcinolone acetonide
- MeSH:
Adult;
Aged;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal/*administration & dosage;
Female;
Follow-Up Studies;
Glucocorticoids/*administration & dosage;
Humans;
Injections;
Macular Edema/diagnosis/*drug therapy/etiology;
Male;
Middle Aged;
Retinal Vein Occlusion/*complications/diagnosis;
Retrospective Studies;
Tomography, Optical Coherence;
Treatment Outcome;
Triamcinolone Acetonide/*administration & dosage;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity;
Vitreous Body
- From:Korean Journal of Ophthalmology
2009;23(4):259-265
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion. METHODS: This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal bevacizumab (1.25 mg/0.05 mL, 22 eyes) or triamcinolone acetonide (4 mg/0.1 mL, 28 eyes) as the only treatment for macular edema secondary to branch retinal vein occlusion; all patients had a post-injection follow-up duration of >24 weeks. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) by optical coherence tomography were measured for up to 24 weeks after injection. RESULTS: BCVA was improved at 1, 4, 8,12 weeks post-injection in the bevacizumab group, and at 1, 4, 8 weeks post-injection in the triamcinolone group. No significant difference was found between the two groups except at 12 weeks. CMT decreased significantly within each group, and no significant difference between groups was found. In the bevacizumab group, no elevated IOP was observed, whereas IOP was significantly increased at 4, 8, and 12 weeks after triamcinolone injection; IOP was therefore significantly different between the two groups. CONCLUSIONS: Intravitreal bevacizumab is a comparatively simple treatment method that can effectively improve BCVA and reduce CMT without ocular and systemic complications. Consequently, intravitreal bevacizumab injections may be useful as both an alternative and primary treatment for macular edema secondary to branch retinal vein occlusion.
